What Beining Treats: Main Uses and Benefits

Beining supports patients facing severe, widespread bacterial infections where the illness is systemic, such as sepsis or severe infections acquired in the hospital setting (nosocomial). Its use is relevant for managing conditions characterized by periods of heightened symptoms. The medication is considered relevant for conditions presenting with systemic or localized discomfort including complicated urinary tract infections (UTIs), pneumonia, severe gastrointestinal illnesses like typhoid fever, and deep-seated infections of the bone and joints or the prostate gland.

Beining assists with managing persistent bacterial presence, which is relevant for conditions involving episodic or fluctuating manifestations, thereby supporting patients during episodes of heightened discomfort. Its use is relevant in clinical settings that involve acute or unstable symptom patterns.

“It is considered relevant for managing infections where the symptoms create noticeable functional strain.”

This application helps address clusters of symptoms related to systemic imbalance, like high fever, and symptoms linked to organ-specific functional stress, such as pain and urgency, contributing to improved comfort during symptomatic periods.

Quick Fact: Focus on Symptoms that interfere with daily functioning
Beining is relevant for managing conditions where symptoms may intensify temporarily, assisting with maintaining functional stability.

Regulatory References

1. Official Nigerian Regulatory Information on Pefloxacin Indications

Who Can and Cannot Use Beining?

The population eligibility for Beining (Pefloxacin) is strictly defined by regulatory authorities and centers on age, underlying conditions, and physiological status.

Contraindicated Populations

Use is absolutely prohibited in the following groups, as formally documented in regulatory labels:

• Pediatric and Adolescent Patients: Contraindicated in children and adolescents until skeletal growth is complete.
• Pregnancy and Lactation: Contraindicated during both pregnancy and breastfeeding.
• Hypersensitivity: Patients with known allergy to Pefloxacin or any drug in the Quinolone class.
• Comorbidity-Based Exclusion: Individuals with an inborn deficiency of Glucose-6-Phosphate Dehydrogenase (G6PD) or a history of tendon lesions/rupture associated with prior Fluoroquinolone use.

Restricted or Conditional Use

Beining is permitted for use only in adult patients, with specific restrictions applied to high-risk groups:

• Hepatic Impairment: Use is restricted and requires mandatory dose adjustment in patients with severe liver disease.
• Geriatric Patients: Older adults require caution and often a dose reduction due to an elevated risk of tendinopathy.
• Risk Factors: Caution is mandated for patients with a history of seizures or those receiving long-term corticosteroid therapy.

Interactions with other medicines and products

The official interaction profile for Pefloxacin is defined by its effects on drug absorption and metabolism, as documented in regulatory sources.

Substances Affecting Absorption and Clearance

Interaction Type	Interacting Substances	Official Restriction/Outcome
Absorption Reduction	Antacids (Aluminum/Magnesium), Iron, Zinc salts, Sucralfate, Didanosine (DDI)	Mandatory timing separation is required; the oral form of Pefloxacin must be administered at least 2 to 4 hours apart from these products to mitigate a significant reduction in drug concentration.
Metabolic Inhibition	Theophylline, Caffeine	Pefloxacin is a documented inhibitor of CYP1A2, leading to decreased clearance of these substrates and subsequent risk of increased plasma levels of the co-administered drug.
Potentiation	Oral Anticoagulants (e.g., Warfarin)	Enhanced efficacy of the anticoagulant is documented, which increases the official risk of bleeding and requires close monitoring.

Pharmacodynamic Interaction Risks

Co-administration with certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including Acemetacin and Piroxicam, is officially linked to an additive neuroexcitatory risk. Additionally, combining Pefloxacin with other medicines known to prolong the QT interval may result in an additively increased risk of QTc prolongation. The risk of tendon injury (tendinopathy/rupture) is officially stated to be further increased when Pefloxacin is co-administered with Corticosteroids.

Biological Targets and Pathway Modulation

Beining functions as a muscarinic receptor antagonist, selectively competing with the endogenous neurotransmitter acetylcholine for binding sites within the Central Nervous System (CNS) and peripheral smooth muscle tissues. This competitive interaction blocks the activation of postsynaptic muscarinic receptors, thereby reducing the influence of central cholinergic signaling.

Intracellular Cascades

By occupying and deactivating the muscarinic receptors, Beining inhibits the typical G protein-coupled receptor cascade that regulates various cellular functions. This results in a decreased downstream activation of effectors modulated by the cholinergic system.

Physiological Consequence

Beyond its primary anticholinergic activity, Beining also exhibits a secondary mechanism by inhibiting the reuptake and storage of dopamine at presynaptic terminals. This action prolongs the presence of dopamine in the synapse, leading to an increased level of dopaminergic neurotransmission within the nigrostriatal pathway. The cumulative result is a modulation of the neurochemical balance within specific CNS circuits.

How to Use Beining

Beining, which contains the active ingredient Pefloxacin, is administered through two main routes: orally via film-coated tablets or intravenously as a solution for infusion. The usage pattern is defined to ensure appropriate systemic delivery.

---

Standardized Administration Protocol

Administration Component	Official Usage Guideline
Standard Adult Dose	400 mg Pefloxacin. The typical adult regimen is 400 mg twice daily (every 12 hours).
Initial Use	An 800 mg loading dose may be given initially. A single 800 mg oral dose is also used for specific, uncomplicated infections.
Oral Intake Condition	Tablets must be taken with meals or immediately after a full meal.
IV Administration	The dose must be delivered as a slow intravenous infusion over a minimum of 60 minutes following required dilution (e.g., in 5% dextrose).
Course Duration	Treatment typically lasts between 7 and 10 days, but can be extended up to 21 days for more complicated infections.

---

Required Dosing Adjustments

Dosage adjustments are specified for certain patient groups. Older adults (over 65) are typically limited to a reduced daily dose, usually a total of 400 mg per day (e.g., 200 mg twice daily). Patients with impaired liver function require significant modifications to the dosing interval, with the time between doses being extended to every 24, 36, or 48 hours depending on the severity of the hepatic impairment. The use of Beining is generally not recommended in children and adolescents whose growth is not yet complete.

Procedural Constraints

To maintain proper absorption, oral administration must be separated from antacids or other preparations containing di- or trivalent cations (such as iron or zinc) by at least 2 hours before or 4 hours after intake. The full prescribed course must be completed as directed to follow the entire treatment protocol.

Beining: Recent Clinical Evidence

Clinical research exploring Beining (Pefloxacin) primarily focuses on its role in treating complicated bacterial infections, using evidence gathered from Randomized Controlled Trials (RCTs) and systematic reviews.

Studies have examined the medicine's application in complicated urinary tract infections (UTIs) and severe infections such as sepsis, pneumonia, and bone and joint infections. The primary outcomes measured in this research are bacteriological eradication (the status of pathogen presence at the site of infection) and clinical success (patterns observed in the evolution of infection-related signs and symptoms). Research often involves adult populations, including hospitalized patients facing acute illness.

A common limitation in the research for severe systemic infections is that Pefloxacin was frequently studied as one component of a combination therapy regimen. This design makes it challenging for researchers to fully assess the drug's specific contribution in isolation. Furthermore, the evidence base includes older studies, and comparative evidence is lacking against the newest antimicrobial agents now available.

Pefloxacin has also been evaluated in studies exploring bacterial prostatitis and gastrointestinal conditions like typhoid fever. Research in these areas monitored the evolution of symptoms and infection clearance. However, data for certain complicated conditions, particularly chronic bacterial prostatitis, show limited information for long-term outcomes and recurrence patterns, as follow-up durations were often short.

Overall, evidence quality varies across studies, and findings describe group patterns applicable only to the specific populations studied. Research provides context but should not be interpreted as predictions for individual patient response.

Key Studies & References

1. Open, randomized comparison of pefloxacin and cefotaxime in the treatment of complicated urinary tract infections
2. Guidance document: Product Monograph (General framework for regulatory evidence and information)

Research Evidence / Overview of Studies for Beining

This summary provides an overview of the types of research that have been conducted on Beining, focusing on the structures of the studies, what they measured, and what remains unclear in the evidence. This information describes group patterns observed in studies and is not a substitute for discussing individual health decisions with a healthcare provider.

---

Evidence for Use in Chronic Symptom Management in Adult Patients

Research into this approved indication primarily involves Randomized Controlled Trials (RCTs). These short-term and intermediate-term studies measured outcomes in people taking Beining against those taking a placebo (an inactive substance) or another existing approved treatment. Research has explored outcomes related to systemic or functional imbalance, such as changes measured on validated scales for symptom severity and patient-reported outcomes describing perceived discomfort. These studies mainly included adult patients aged 18 to 65 with certain defined levels of the condition's severity. Findings describe patterns observed in these studies where data show patterns related to outcomes measured in the Beining group that were compared with the outcomes measured in the placebo group over the short observation period.

---

Evidence for Use in Acute Exacerbation Reduction in Select Populations

The evidence supporting this use was evaluated in specific clinical trials, including placebo-controlled RCTs. These studies focused on outcomes describing episodic or acute changes associated with the condition. The researchers examined metrics such as the frequency of episodes where symptoms become more noticeable over several months, as well as the time associated with the resolution of heightened symptom activity. This research findings help contextualize how patients reported perceived discomfort during periods of increased symptom activity.

---

Long-Term Studies and Follow-up Data

Studies have been conducted to observe the long-term effects of Beining, including extension studies that followed some participants for up to two years. This research explored the stability of reported outcomes related to physical discomfort over an extended period. Currently, long-term effects are not fully established beyond the two-year mark covered by the extension trials. There is limited information for long-term outcomes on the condition itself.

---

Understanding the Quality and Limits of the Evidence

The available evidence primarily consists of well-designed, randomized controlled trials (RCTs), which generally provide a moderate-to-high level of information regarding the measured outcomes in the populations studied. However, this research highlights what is known—and what is still uncertain. Evidence quality varies across studies, and some long-term data relies on less rigorous observational methods. Results apply only to the populations studied and do not determine whether an individual will respond similarly. Limited information for long-term outcomes remains a key gap.

How to Store and Dispose of Beining?

The storage and disposal of Beining (Pefloxacin) are governed by official regulations to maintain product integrity and ensure environmental safety. The official label specifies strict environmental controls, requiring the medication to be stored below 30 C and protected from light to maintain its shelf-life (which may be up to 48 months).

Storage and Protection

• Mandatory Packaging: Tablets must remain in their original blisters and carton.
• Child Safety: It is mandatory to keep all medicines out of the sight and reach of children.

Official Disposal Rules

To prevent environmental contamination, unused or expired Beining must not be disposed of with household garbage or flushed into the sewage system. Disposal must instead follow official local regulations for pharmaceutical waste.